文献速递肝病

雷迪帕韦-索磷布韦联合或不联合利巴韦林治疗6-11岁儿童慢性丙型肝炎的安全性与疗效

Safety and Efficacy of Ledipasvir-Sofosbuvir With or Without Ribavirin for Chronic Hepatitis C in Children Ages 6-11.
PubMed 文献 · Hepatology · 2018-11-17

一项开放标签研究评估雷迪帕韦-索磷布韦联合或不联合利巴韦林治疗6至<12岁慢性丙型肝炎病毒感染儿童的疗效与安全性,共纳入92例患者,总体SVR12率为99%(91/92;95%CI 94%-100%),最常见不良事件为头痛和发热,结论为该方案耐受良好且高效。

要点

  • 6至<12岁慢性HCV感染儿童接受雷迪帕韦-索磷布韦联合或不联合利巴韦林治疗,总体SVR12率为99%(91/92;95%CI 94%-100%)。
  • 最常见不良事件为头痛和发热;1例患者发生3次严重不良事件,研究者认为与研究治疗无关。
  • 雷迪帕韦、索磷布韦及其主要代谢物GS-331007的AUC和Cmax均在预设的药代动力学等效界值(50%-200%)内。

核心结论

  • 雷迪帕韦-索磷布韦在6至<12岁慢性HCV感染儿童中耐受良好且高度有效。

研究设计与样本

  • 开放标签研究,纳入92例6至<12岁慢性HCV感染儿童(基因1型88例、基因3型2例、基因4型2例),中位年龄9岁(范围6-11岁)。
  • 患者接受雷迪帕韦45 mg-索磷布韦200 mg(即两片22.5/100 mg固定剂量复方片)每日一次,联合或不联合利巴韦林,疗程12或24周,取决于HCV基因型和肝硬化状态。
  • 12例患者接受密集药代动力学采样以确认雷迪帕韦和索磷布韦剂量是否合适。
  • 多数患者为围产期感染(97%)且为初治(78%);2例确诊肝硬化,55例纤维化程度未知。

主要发现

  • 总体SVR12率为99%(91/92;95%CI 94%-100%)。
  • 唯一未达到SVR的患者在完成12周治疗后4周复发。
  • 最常见不良事件为头痛和发热。
  • 1例患者发生3次严重不良事件(牙脓肿、腹痛和胃肠炎),研究者认为与研究治疗无关。
  • 索磷布韦、其主要代谢物GS-331007及雷迪帕韦的AUC和Cmax值均在预设的药代动力学等效界值(50%-200%)内,与雷迪帕韦和索磷布韦2/3期研究中的成人值相比。

关键数值与推荐

  • 主要疗效终点为治疗结束后12周的持续病毒学应答(SVR12)。
  • 雷迪帕韦45 mg-索磷布韦200 mg以两片22.5/100 mg固定剂量复方片每日一次给药,联合或不联合利巴韦林,疗程12或24周,取决于HCV基因型和肝硬化状态。
  • 药代动力学等效界值预设为成人值的50%-200%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Currently, there are no interferon-free treatments available for hepatitis C virus (HCV)-infected patients younger than 12 years. We evaluated the safety and effectiveness of the all-oral regimen ledipasvir-sofosbuvir ± ribavirin in HCV-infected children aged 6 to <12 years. In an open-label study, patients aged 6 to <12 years received ledipasvir 45 mg-sofosbuvir 200 mg as two fixed-dose combination tablets 22.5/100 mg once daily, with or without ribavirin, for 12 or 24 weeks, depending on HCV genotype and cirrhosis status. The primary efficacy endpoint was sustained virologic response 12 weeks after therapy (SVR12). Twelve patients underwent intensive pharmacokinetic sampling to confirm the appropriateness of the ledipasvir and sofosbuvir dosages. Ninety-two patients were enrolled (88 genotype 1, 2 genotype 3, and 2 genotype 4), with a median age of 9 years (range, 6-11). Most were perinatally infected (97%) and treatment-naive (78%). Two were confirmed to have cirrhosis, while the degree of fibrosis was unknown in 55 patients. The overall SVR12 rate was 99% (91/92; 95% confidence interval, 94%-100%). The single patient not reaching SVR relapsed 4 weeks after completing 12 weeks of treatment. The most common adverse events were headache and pyrexia. One patient had three serious adverse events, which were considered to be not related to study treatment: tooth abscess, abdominal pain, and gastroenteritis. The area under the concentration-time curve and maximum concentration values for sofosbuvir, its primary metabolite GS-331007, and ledipasvir were within predefined pharmacokinetic equivalence boundaries (50%-200%) compared to values in adults in phase 2/3 of the ledipasvir and sofosbuvir studies. Conclusion: Ledipasvir-sofosbuvir was well tolerated and highly effective in children 6 to <12 years old with chronic HCV.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Murray KF, Balistreri WF, Bansal S, et al. Safety and Efficacy of Ledipasvir-Sofosbuvir With or Without Ribavirin for Chronic Hepatitis C in Children Ages 6-11. Hepatology. 2018. PMID: 30070726. doi:10.1002/hep.30123

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。